Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

pfizer aps - sulfasalazin - enterotabletter - 500 mg

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

paranova danmark a/s - sulfasalazin - tabletter - 500 mg

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

2care4 aps - sulfadiazin, trimethoprim - oral pasta - 288,3 + 58 mg/g

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

cenavisa s.l. - sulfadiazin, trimethoprim - injektionsvæske, opløsning - 200+40 mg/ml

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

macure healthcare limited - sulfamethoxazol, trimethoprim - koncentrat til infusionsvæske, opløsning - 80+16 mg/ml

European Union - Danish - EMA (European Medicines Agency)

mylan pharmaceuticals limited - atazanavir (as sulfate) - hiv infektioner - antivirale midler til systemisk anvendelse - atazanavir mylan, administreret sammen med lavdosis ritonavir, er indiceret til behandling af hiv 1-inficerede voksne og pædiatriske patienter 6 år og ældre i kombination med andre antiretrovirale lægemidler. baseret på tilgængelige virologisk og kliniske data fra voksne patienter, ingen fordele forventes i patienter med stammer, der er resistente over for flere proteasehæmmere (≥ 4 pi mutationer). der er meget begrænsede data tilgængelige fra børn i alderen 6 til under 18 år. valget af atazanavir mylan i behandling erfarne voksne og pædiatriske patienter, der bør være baseret på individuelle viral resistens test og patientens behandling, historie.

European Union - Danish - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - antitrombotiske midler - xarelto, co-gives sammen med acetylsalicylsyre (asa) alene eller sammen med asa plus clopidogrel eller ticlopidin, der er indiceret til forebyggelse af atherothrombotic hændelser hos voksne patienter efter en akut koronar syndrom (acs) med forhøjet kardiale biomarkører. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. forebyggelse af venøs tromboembolisme (vte) hos voksne patienter, der gennemgår valgfri hofte- eller knæskifteoperation. behandling af dyb venøs trombose (dvt) og lungeemboli (pe), og forebyggelse af recidiverende dvt og pe i voksne. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

European Union - Danish - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - antitrombotiske midler - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

orifarm a/s - glycopyrroniumbromid, neostigminmethylsulfat - injektionsvæske, opløsning - 0,5 + 2,5 mg/ml

Denmark - Danish - Lægemiddelstyrelsen (Danish Medicines Agency)

smartpractice denmark aps - alfa-amylcinnamaldehyd, almindelig slåenlav (evernia prunastri), benzocain, benzylparahydroxybenzoat, butylparahydroxybenzoat, chlorquinaldol, cinchocainhydrochlorid, cinnamaldehyd, cinnamylalkohol, clioquinol, cyclohexylbenzothiazylsulfenamid, dibenzothiazyldisulfid, dipentamethylenthiuramdisulfid, diphenylguanidin, disulfiram, epoxyresin, ethylendiamindihydrochlorid, ethylparahydroxybenzoat, eugenol, geraniol, hydroxycitronellal, isoeugenol, kaliumdichromat, koboltchlorid, kolofonium, lanolinalkohol, mercaptobenzothiazol, methylchlorisothiazolinon, methylparahydroxybenzoat, morpholinylmercaptobenzothiazol, n-cyclohexyl-n-phenylparaphenylendiamin, n-hydroxymethylsuccinimid, n-isopropyl-n-phenylparaphenylendiamin, n,n-diphenylparaphenylendiamin, neomycinsulfat, nikkelsulfat, p-tert butylphenol formaldehyd harpiks, paraphenylendiamin, perubalsam, propylparahydroxybenzoat, quaternium-15, tetracainhydrochlorid, tetramethylthiurammonosulfid, thiomersal, thiram, zinkdibutyldithiocarbamat, zinkdiethyldithiocarbamat - plaster til provokationstest